Pharmacogenetic determinants of codeine induction by rifampin: The impact on codeine's respiratory, psychomotor and miotic effects

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 1, 1997, Pages 330-336

  Caraco, Yoseph ^a,b   Sheller, James ^a   Wood, Alastair J J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; MORPHINE DERIVATIVE; RIFAMPICIN;

ADULT; ARTICLE; BREATHING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MIOSIS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; VERTIGO;

ADULT; CODEINE; CYTOCHROME P-450 CYP2D6; DEALKYLATION; DEBRISOQUIN; DRUG INTERACTIONS; HUMANS; MALE; MIOTICS; NARCOTICS; PHARMACOGENETICS; PSYCHOMOTOR PERFORMANCE; RESPIRATION; RIFAMPIN;

EID: 0030959379     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. ALVAN, G., BECHTEL, P., ISELIUS, L. AND GUNDERT-RAMY, U.: Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39: 533-537, 1990.
2. BACIEWIEZ, A. M. AND SELF, T. H.: Rifampin drug interactions. Arch. Int. Med. 144: 1667-1671, 1984.
3. 3H] codeine phosphate in man and in the dog. Arzneim. Forsch. 28: 308-311, 1978.
4. BIRGERSSON, C., BLANCK, A., WOODHOUSE, K., MELLSTROM B., VON BAHR, C.: Comparative metabolism of debrisoquine, 7-ethoxyresorufin and benzo-(a)pyrene in liver microsomes from humans, and rats treated with cytochrome P-450 inducers. Acta Pharmacol. Toxicol. 57: 117-120, 1985.
5. BOCK, K. W., SCHRENK, D., FORSTER, A., GRIESE, E. U., MORIKE, K., BROCKMETER, D., EICHELBAUM, M.: The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltranaferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4: 209-218, 1994.
6. BROSEN, K.: Recent developments in hepatic drug oxidation. Implication for clinical pharmacokinetics. Clin. Pharmacokinet. 18: 220-239, 1990.
7. CARACO, Y., SHELLER, J. AND WOOD, A. J. J.: Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J. Pharmacol. Exp. Ther. 278: 1165-1174, 1996a.
8. CARACO, Y., TATEISHI, T., GUENGERICH, F. P., WOOD, A. J. J.: Microsomal codeine N-demethylation: Cosegregation with cytochrome P4503A4 activity. Drug, Metab. Dispos. 24: 761-764, 1996b.
9. CHEN, Z. R., IRVINE, R. J., SOMOGYI, A. A., BOCHNER, F.: μ. receptor binding of some commonly used opioids and their metabolites. Life. Sci. 48: 2165-2171, 1991.
10. DESMEULES, J., GASCON, M. P., DAYER. P., MAGISTRIS, M.: Impact of environmental and genetic factors on codeine analgesia. Eur. J. Clin. Pharmacol. 41: 23-26, 1991.
11. EICHELBAUM, M., MINESHITA, S., UHNHAUS, E. E., ZEKRON, C.: The influence of enzyme induction on polymorphic sparteine oxidation. Br. J. Clin. Pharmac. 22: 49-53, 1986.
12. EICHELBAUM, M., GROSS, A. S.: The genetic polymorphism of debrisoquine/ sparteine metabolism-clinical aspect. Pharmacol. Ther. 46: 377-394, 1990.
13. FAZIO, A.: Oral contraceptive drug interactions: Important considerations. South. Med. J. 84: 997-1002, 1991.
14. GED, C., ROUILLON, J. M., PICHARD, L., COMBALBERT, J., BRESSOT, N., BORIES, P. MICHEL, H., BEAUNE, P., MAUREL, P.: The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br. J. Clin. Pharmacol. 28: 373-387, 1989.
15. GUENGERICH. F. P.: Catalytic selectivity of human cytochrome P450 enzymes: Relevance to drug metabolism and toxicity. Toxicol. Lett. 70: 133-138, 1994.
16. HEIMARK, L. D., GIBALDI, M., TRAGER, W. F., O'REILLY, R. A., GOULART, D. A.: The mechanism of warfarin-rifampin drug interaction in humans. Clin. Pharmacol. Ther. 42: 388-394, 1987.
17. HULL, J. H., FINDLAY, J. W. A., ROGERS, J. F., WELCH, R. M., BUTZ, R. F. BUSTRACK, J. A.: An evaluation of the effects of smoking on codeine pharmacokinetics and bioavailability in normal human volunteers. Drug Intell. Clin. Pharmacol. 16: 849-854, 1982.
18. LARREY, D., BABANY, G., TINEL. M., FRENEAUX, E., AMOUYAL, G., HABERSETZER, F. LETTERON, P., PESSAYRE, D.: Effect of liver disease on dextromethorphar oxidation capacity and phenotype: A study in 107 patients. Br. J. Clin Pharmacol. 28: 297-304, 1989.
19. LASAGNA, L., DE KORNFELD, T. J.: Analgesic potency of normorphine in patients with postoperative pain. J. Pharmacol. 124: 260-263, 1958.
20. LECLERCQ, V., DESAGER, P., HORMANS, Y., VAN NIEUWENHUYZE, Y., HARVENGT, C.: Influence of rifampin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. Inter. J. Clin. Pharm. Ther. Toxic. 27: 593-598, 1989.
21. MATHER, L. E.: Analgesic drugs, Nimmo, W. S., Smith, G., In Anaesthesia. ed. by W. S. Nimmo and G. Smith, pp. 43-104, Blackwell Scientific Publications. Oxford UK, 1989.
22. MODRY, D. L., STINSON, E. B., OVER, P. E., JAMIESON, S. W., BALDWIN, J. C., SHUMWAY, N. E.: Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 39: 313-314, 1985.
23. MORTIMER, Ö., PERSSON, K., LADONA, M. G., SPALDING, D., ZANGER, U. M., MEYER, U. A., RANE, A.: Polymorphic formation of morphine from codeine in pour and extensive metabolizers of dextromethorphan: Relationship to the presence of immunoidentified cytochrome P-450IID1. Clin. Pharmacol. Ther. 47: 27-35, 1990.
24. NIELSEN, M. D., BROSEN, K., GRAM, L. F.: A dose effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br. J. Clin. Pharmacol. 29: 299-304, 1990.
25. OHNHAUS, E. E., BROCKMEYER, N., DYLEWICZ, P., HABICHT, H.: The effect of antipyrine and rifampin on the metabolism of diazepam. Clin. Pharmacol. Ther. 42: 148-156, 1987.
26. PRICE, D. E., MEHTA, A., PARK, B. K., HAY, A., FELLY, M. P.: The effect of low dose phenobarbitone on three indices of hepatic microsomal enzyme induction Br. J. Clin. Pharmacol. 22: 744-747, 1986.
27. READ, D. J. C.: A clinical method for assessing the ventilatory response to carbon dioxide. Aust. Ann. Med. 1: 20-32, 1967.
28. ROGERS, J. F., FINDLAY, J. W. A., HULL, J. H., BUTZ, R. F., JONES. E. C., BUSTRACK, J. A., WELCH, R. M.: Codeine disposition in smokers and nonsmokers. Clin. Pharmacol. Ther. 32: 218-227, 1982.
29. SCHELLENS, J. H. M., VAN DER WART, J. H. F., BRUGMAN, M., BREIMER, D. D.: Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cock-tail" study design. J. Pharmacol. Exp. Ther. 249: 638-645, 1989.
30. SHAHEEN, O., BIOLLAZ, J., KOSHAKJI, R. P., WILKINSON, G. R., WOOD, A. J. J.: Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. Clin. Pharmacol. Ther. 45: 439-443, 1989.
31. SINDRUP, S. H., BROSEN, K., BJERRING, P., ARENDT-NIELSEN, L., LARSEN, U., ANGELO, H. R. AND GRAM, L. F.; Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin. Pharmacol. Ther. 49: 686-693, 1991.
32. SNAFILIPPO, G.: Contributo sperimentale all' ipotesi della smetilazione della codeine nell' organismo. I. Inflenze della dose sull' assuefazione alla codeine. II. assuefazione alla codeine attenuta con somministrazione prolungata di morfina. Boll. Soc. Ital. Biol. Sper. 24: 723-726, 1948.
33. STEINER, E., ISELIUS, L., ALVAN, G., LINDSTEN, J., SJOQVIST, F.: A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin. Pharmacol. Ther. 38: 394-401, 1985.
34. TEUNISSEN, M. W. E., BAKKER, W., VAN DER TORREN, J. E. M., BREIMER, D. D.: Influence of rifampin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. Br. J. Clin. Pharmac. 18: 701-706, 1984.
35. TUCKER, G. T.: Clinical implications of genetic polymorphism in drug metabolism. J. Pharm. Pharmacol. 46: 417-424, 1994.
36. VENKATESAN, K.: Pharmacokinetic drug interactions with rifampin. Clin. Pharmacokinet. 22: 47-65, 1992.
37. WECHSLER, D.: A Manual for the Wechsler Adult Inteligence Scale. Psychological Corporation, New York, 1981.
38. WEDLUND, P. J., ASLANIAN, W. S., MCALLISTER, C. B., WILKINSON, G. R. AND BRANCH, R. A.: Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism. Clin. Pharm. Ther. 36: 773-780, 1984.
39. WILKINSON, G. R., GUENGERICH, F. P., BRANCH, R. A.: Genetic polymorphism of S-mephenytoin hydroxylation. Pharmac. Ther. 43: 53-76, 1989.
40. WOLFF, T., STRECKER, M.: Lack of relationship between debrisoquine 4-hydroxylation and other cytochrome P-450 dependent reactions in rat and human liver. Biochem. Pharmacol. 34: 2593-2598, 1985.
41. WRIGHTON, S. A., STEVENS, J. C.: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22: 1-21, 1992.
42. YUE, Q. Y., SVENSSON, J. O., ALM, C., SJÖQVIST, F., SAWE, J.: Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br. J. Clin. Pharmacol. 28: 639-645, 1989.
43. YUE, Q. Y., HASSELSTROM, J., SVENSSON, J. O., SAWE, J.: Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: Comparison between extensive and poor hydroxylators of debrisoquine. Br. J. Pharmac. 31: 635-642, 1991.
44. YUE, Q. Y., TOMSON, T. AND SAWE. J.: Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics 4: 193-198, 1994.